DK0416951T3 - Lægemidler indeholdende salmeterol og fluticason - Google Patents

Lægemidler indeholdende salmeterol og fluticason

Info

Publication number
DK0416951T3
DK0416951T3 DK90309846.5T DK90309846T DK0416951T3 DK 0416951 T3 DK0416951 T3 DK 0416951T3 DK 90309846 T DK90309846 T DK 90309846T DK 0416951 T3 DK0416951 T3 DK 0416951T3
Authority
DK
Denmark
Prior art keywords
fluticasone
medicines containing
salmeterol
containing salmeterol
inhalation
Prior art date
Application number
DK90309846.5T
Other languages
Danish (da)
English (en)
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0416951(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0416951T3 publication Critical patent/DK0416951T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK90309846.5T 1989-09-08 1990-09-07 Lægemidler indeholdende salmeterol og fluticason DK0416951T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
DK0416951T3 true DK0416951T3 (da) 1994-02-14

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90309846.5T DK0416951T3 (da) 1989-09-08 1990-09-07 Lægemidler indeholdende salmeterol og fluticason

Country Status (20)

Country Link
EP (1) EP0416951B1 (OSRAM)
JP (1) JP3042867B2 (OSRAM)
AT (1) ATE99941T1 (OSRAM)
BE (1) BE1003053A3 (OSRAM)
CA (1) CA2024916C (OSRAM)
CH (1) CH680983C9 (OSRAM)
DE (2) DE69005951T2 (OSRAM)
DK (1) DK0416951T3 (OSRAM)
ES (1) ES2062392T3 (OSRAM)
FR (1) FR2651677B1 (OSRAM)
HK (1) HK18695A (OSRAM)
HU (1) HU211272A9 (OSRAM)
IE (1) IE65535B1 (OSRAM)
IL (1) IL95590A (OSRAM)
IT (1) IT1241996B (OSRAM)
LU (1) LU90392I2 (OSRAM)
NL (1) NL990012I2 (OSRAM)
NZ (1) NZ235221A (OSRAM)
PH (1) PH27594A (OSRAM)
SG (1) SG166294G (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
CA2317999C (en) 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
ES2546830T3 (es) * 2000-08-05 2015-09-29 Glaxo Group Limited Éster S-fluorometilo del ácido 6alfa,9alfa-difluoro-17alfa-[(2-furanilcarboxil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta-1,4-dieno-17beta-carbotioico como agente antiinflamatorio
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CN1302007C (zh) 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.-硫代羧酸酯衍生物
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1471895B2 (en) 2002-02-04 2012-03-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
AU2003221482A1 (en) * 2002-03-04 2003-09-16 Boehringer Ingelheim Pharma Gmbh And Co. Kg Novel cinnamate salts, method for production and use thereof as medicaments
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
CA2534934A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
KR20060135873A (ko) * 2004-03-12 2006-12-29 씨아이피엘에이 엘티디. 살메테롤 흡입 제제
UA93031C2 (uk) 2004-07-16 2011-01-10 Алміралл, С.А. Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора
PT2063940E (pt) 2006-12-22 2012-03-27 Almirall Sa Dispositivo de inalação para fármacos em forma de pó
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3106149B1 (en) 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
MX2015015132A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
BE1003053A3 (fr) 1991-11-05
JP3042867B2 (ja) 2000-05-22
ATE99941T1 (de) 1994-01-15
NL990012I1 (nl) 1999-07-01
ES2062392T3 (es) 1994-12-16
NL990012I2 (nl) 1999-09-01
SG166294G (en) 1995-06-16
CA2024916C (en) 2002-07-09
IT9048260A1 (it) 1992-03-07
IT9048260A0 (it) 1990-09-07
EP0416951B1 (en) 1994-01-12
PH27594A (en) 1993-08-31
EP0416951A1 (en) 1991-03-13
NZ235221A (en) 1992-11-25
IT1241996B (it) 1994-02-02
HU211272A9 (en) 1995-11-28
CH680983A5 (OSRAM) 1992-12-31
IE65535B1 (en) 1995-11-01
DE69005951T2 (de) 1994-05-26
FR2651677B1 (fr) 1993-08-06
JPH03167120A (ja) 1991-07-19
CH680983C1 (OSRAM) 2008-06-25
CA2024916A1 (en) 1991-03-09
CH680983C9 (OSRAM) 2008-08-15
LU90392I2 (fr) 1999-06-28
DE69005951D1 (de) 1994-02-24
IL95590A (en) 1996-06-18
DE19975040I2 (de) 2006-07-13
HK18695A (en) 1995-02-17
IL95590A0 (en) 1991-09-16
FR2651677A1 (fr) 1991-03-15
IE903256A1 (en) 1991-03-13

Similar Documents

Publication Publication Date Title
DK0416951T3 (da) Lægemidler indeholdende salmeterol og fluticason
DE69002718D1 (de) Medikamente.
CA2123909A1 (en) New combination of formoterol and budesonide
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
NO20065102L (no) Medikamenter
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
GB9523442D0 (en) Calcitonin salmon analogues,their preparation,medicinal use and use as analytical agents
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
MY111155A (en) Medicaments
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
RU93003454A (ru) Лекарственный препарат